A new review was published in Volume 16 of Oncotarget on June 25, 2025, titled "Challenges and resistance mechanisms to EGFR ...

Merus N.V., an oncology-focused company, announced the publication of research on petosemtamab, a bispecific antibody targeting EGFR and LGR5, in the journal "Cancers." The study highlights the ...

However, optimal implementation of EGFR inhibitors as radiosensitizers depends, in part, on a better understanding of the mechanisms of radiosensitization.

An expert discussed how the understanding of resistance mechanisms can help care teams develop a global treatment strategy for EGFR-mutated non-small cell lung cancer.

This newest approval for amivantamab is the second approval in 6 months for the EGFR and MET bispecific antibody.

A new research paper titled "Inhibiting BRAF/EGFR/MEK suppresses cancer stemness and drug resistance of primary colorectal cancer cells" has been published in Oncotarget.

Ivonescimab (AK112) has been dosed for the first time in the phase 3 HARMONi/AK112-301 study of ivonescimab vs the combination of tislelizumab (BGB-A317) plus chemotherapy as first-line therapy for ...

Patritumab Deruxtecan Data at ASCO Demonstrates Tumor Response Across Multiple Resistance Mechanisms in Patients with Advanced EGFR-Mutated NSCLC ...

In May, Eli Lilly snagged FDA approval for its anti-VEGF antibody Cyramza to treat NSCLC patients alongside EGFR med Tarceva, based on phase 3 data showing the combo outshone Tarceva alone.

Since its approval in April 2018, osimertinib has been widely adopted as first-line therapy for patients with advanced EGFR-mutant non -small cell lung cancer (NSCLC). Understanding osimertinib ...